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Learning Objectives

•
•
•
•

Results

Describe the development of the GWU COVID-19 biorepository
Create a profile of patients enrolled during the acute phase
Explore the value of a COVID-19 biorepository in helping answer
important epidemiological/scientific research questions
Discuss lessons learned in establishing the GWU COVID-19
Biorepository

Background and Purpose
•

First reported in December 2019, the novel coronavirus named
(SARS-CoV-2), which causes the severe acute respiratory
syndrome known as COVID-19, has spread rapidly across the world.
• SARS-CoV-2 RNA has been detected not only in the respiratory
tract but also in blood, urine, and stool specimens.
• In the greater Washington, DC region (DMV), which includes parts of
Maryland and Virginia and houses the nation’s capital, there have
been 1,057,944 cases and 19,417 deaths reported since March 5
and continues to grow.
• We have established a prospective longitudinal cohort study of
patients diagnosed with COVID-19 at the George Washington
University, in Washington, DC with plans for follow-up over the
course of one year.
Goal of the biorepository:
• Collect both biospecimens and clinical data to promote scientific
inquiry into the basic science, pathogenesis, and mechanisms of the
virus causing COVID-19

Project Description

Acute
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92 COVID-19 PCR positive participants have been enrolled
since April 2020 and enrollment and data collection are
ongoing. Healthy controls are also being enrolled as a
comparison group and 13 have been enrolled so far. An
overview of patient enrollment according to follow-up time
period is shown in Table 1. The enrollment, follow-up, and
data entry process is shown in Figure 2.
Table 1. Number of COVID-19 Patients Enrolled at Various Timepoints

Number of COVID19 patients (N=92)

Enrolled at
Baseline (1-11
Days)

Enrolled at 10weeks

Enrolled at 6months

Enrolled at 12months

49 (53.3%)

19 (20.7%)

21 (22.8%)

3 (3.3%)

Figure 2. Process overview of Biobank enrollment and data entry

Participant Recruitment: Confirmed SARS-CoV-2 positive patients
identified from chart review or physician referral are invited to participate
through informed signed consent under an IRB approved protocol.
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Figure 1: COVID-19 Specimen Collection Time Points

Specimen Collections:
• Nasopharyngeal or oropharyngeal swabs for RT-PCR
• Serological tests from adult patients: 30mL in acute phase and 50mL
in post-acute phase including those with post-acute sequelae
• Urine studies
• Rectal, vaginal, and penile swabs are collected to detect mucosal
shedding at follow-up time points
Clinical Data:
• Clinical interviews conducted by the research team
• Chart abstractions performed
• De-identified clinical data entered into a secure RedCap database

Given patient retention and data collection challenges exist,
various approaches have been implemented to optimize data
and specimen collection.
Retention strategies have included:
● Verification of multiple sources of contact information at
baseline
● Utilization of Cisco Jabber app technology to contact
enrolled patients
● The implementation of a COVID-19 biorepository email
account to send scheduled reminder notifications to patients
● Reimbursement by providing patients gift cards at follow-up
visits
● Scheduling future visits during baseline
● Bolstering data collection through data extraction from
electronic medical records

• The creation and establishment of a COVID-19 biorepository will
be a valuable resource for scientific investigators to study the
pathogenesis and mechanisms of the SARS-CoV-2 virus in the
acute phase and longitudinally in follow-up as well as in patients
with post acute sequelae of COVID-19.
• Willingness of communities of color to participate in this study
and support better understanding of COVID-19 is invaluable
towards the study of health disparities facing this community.
• A strong participant education effort is important to coincide with
this project, in particular, for how this contribution would support
understanding of COVID-19, which has been a major
motivational factor towards participation.
• It is important to engage participants as stakeholders in the
research process and develop processes to feedback results of
the study to the community.
• Study retention beyond acute enrollments has been a challenge,
but instituting processes for improved communication including a
variety of approaches from phone calls, messages, and e-mails,
as well as incentives has helped improve retention.
• Teamwork has been critical for making this bio-repository a
success and has included collaboration across clinical,
enrollment, abstraction, and laboratory teams as well as scientific
investigators.
• Establishing systems for coordination including through many
team workers working virtually through the pandemic is important
for a successful project. This includes establishing clear defined
roles and virtual systems and databases that allow teams to work
both on-site and remotely.
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